New Approvals In Spotlight As China Gears For National Congress
Proposed Biosecurity Law Also Gains Momentum
Executive Summary
In a sign that attention in China may be shifting back to more routine regulatory work as the local coronavirus outbreak appears to recede, authorities have granted approvals to multiple new drugs for cancer and rare diseases, as the government gears up to hold its delayed annual congress in Beijing.
You may also be interested in...
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
China's New Hong Kong Security Law To Derail Biotech IPOs?
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On
More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.
Need a specific report? 1000+ reports available
Buy Reports